IKT

Inhibikase Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 9/10
  • Momentum↓ 4/10
Inhibikase Therapeutics sales and earnings growth
IKT Growth
Great
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↑ 117.65%
  • FCF Y/Y↓ -48.62%
Inhibikase Therapeutics gross and profit margin trends
IKT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -217.00%
Inhibikase Therapeutics net debt vs free cash flow
IKT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Inhibikase Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗